Welcome to our dedicated page for G1 Therapeutics news (Ticker: GTHX), a resource for investors and traders seeking the latest updates and insights on G1 Therapeutics stock.
G1 Therapeutics, Inc. (Nasdaq: GTHX) is a commercial-stage oncology biopharmaceutical company committed to developing next-generation therapies to improve the lives of cancer patients. The company is based in Research Triangle Park, N.C., and leverages its proprietary kinase drug discovery platform to advance a pipeline of innovative compounds. G1's flagship product, COSELA® (trilaciclib), has been approved by the FDA to decrease the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer (ES-SCLC).
In addition to COSELA, G1 Therapeutics is actively developing and evaluating trilaciclib in combination with other anti-cancer therapies. One notable project is the global, multi-center, randomized, placebo-controlled Phase 3 trial known as PRESERVE 2, which investigates trilaciclib in patients with metastatic triple-negative breast cancer (mTNBC). Preliminary results have shown promising survival benefits, indicating trilaciclib’s potential to protect bone marrow and enhance patient outcomes during cytotoxic therapy.
The company also engages in strategic partnerships to broaden its impact. For instance, G1 Therapeutics has entered agreements with companies like Pepper Bio and Jupiter Bioventures to advance the clinical development and commercialization of lerociclib, another promising CDK4/6 inhibitor. These collaborations aim to explore lerociclib's efficacy in treating various cancers, including HCC and radioprotection uses.
On the financial front, G1 Therapeutics reported revenues of $82.5 million for the full year 2023, reflecting significant growth from $51.3 million in the previous year. The company's ongoing commitment to innovation and strategic collaborations underscores its role as a key player in oncology therapeutics.
For more information, visit G1 Therapeutics and follow them on Twitter and LinkedIn.
G1 Therapeutics (Nasdaq: GTHX) announces the appointment of William C. Roberts as Vice President of Investor Relations and Corporate Communications. With nearly 30 years of experience in life sciences, Roberts will bolster G1's communication strategy, especially as the company approaches the approval of trilaciclib for small cell lung cancer. Concurrently, G1 is granting him options to purchase 50,000 shares of common stock at a price equal to the closing stock price on January 4, 2021, vested over four years.
G1 Therapeutics has announced positive results from its randomized Phase 2 trial of trilaciclib in metastatic triple-negative breast cancer (mTNBC), showing a significant improvement in overall survival (OS) when combined with a chemotherapy regimen of gemcitabine/carboplatin. Median OS was not reached for patients on trilaciclib compared to 12.6 months with chemotherapy alone. A pivotal trial is set to begin in early 2021 to confirm these findings. Additionally, updated data for the oral selective estrogen receptor degrader rintodestrant indicated clinical activity in ER+, HER2- breast cancer.
G1 Therapeutics, Inc. (Nasdaq: GTHX) announced that new CEO Jack Bailey and CMO Raj Malik, M.D. will provide a company update at the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020, at 1:00 p.m. ET. The company is focused on developing therapies to improve cancer treatment outcomes, including trilaciclib for chemotherapy patients and rintodestrant, an oral selective estrogen receptor degrader for ER+ breast cancer. The presentation will be accessible via the company’s Events & Presentations page on their website.
G1 Therapeutics (GTHX) announced promising final overall survival data from its Phase 2 trial for trilaciclib in metastatic triple-negative breast cancer (mTNBC), demonstrating a significant median overall survival benefit when combined with gemcitabine/carboplatin chemotherapy. The results will be presented at the 2020 San Antonio Breast Cancer Symposium on December 9. Additionally, updated findings on rintodestrant, a potential oral selective estrogen receptor degrader, will also be shared. The company anticipates a pivotal trial for trilaciclib to commence in 2021.
G1 Therapeutics (GTHX) announces CEO Jack Bailey will present a company update at the Stifel 2020 Virtual Healthcare Conference on November 18, 2020, at 11:20 a.m. ET. Investors can access the live and archived webcast on the company's website.
G1 Therapeutics focuses on developing innovative cancer therapies, including trilaciclib, a treatment designed to enhance chemotherapy outcomes, and rintodestrant, a potential leading drug for ER+ breast cancer. The company has out-licensed rights for its oral CDK4/6 inhibitor, lerociclib.
G1 Therapeutics (GTHX) announced the acceptance of its New Drug Application (NDA) for trilaciclib in small cell lung cancer (SCLC) for Priority Review, with a PDUFA action date set for February 15, 2021. The application is backed by positive data from three clinical trials demonstrating trilaciclib's benefits in reducing myelopreservation during chemotherapy. The company also reported a net loss of $11.7 million for Q3 2020, down from $32.4 million in Q3 2019. G1 anticipates ending 2020 with cash reserves between $200-$205 million, a revision from earlier forecasts.
G1 Therapeutics, a clinical-stage oncology company, announced a webcast and conference call on November 4, 2020, at 4:30 p.m. ET to provide a corporate and financial update for Q3 2020. Interested participants can access the call by dialing the provided numbers and using the conference code. G1 Therapeutics focuses on developing next-generation therapies for cancer, including trilaciclib and rintodestrant, and has out-licensed its oral CDK4/6 inhibitor, lerociclib, in 2020. For more details, visit their website.
G1 Therapeutics, Inc. (Nasdaq: GTHX) announced that four presentations on the myelopreservation benefits of trilaciclib will be showcased at the North America Conference on Lung Cancer on October 16-17. Trilaciclib is an investigational therapy aimed at improving outcomes in cancer patients undergoing chemotherapy. The presentations include studies highlighting its effectiveness in reducing the need for growth factors and transfusions, particularly for patients with small cell lung cancer. The FDA accepted the New Drug Application for trilaciclib in August 2020, with a review date set for February 15, 2021.
G1 Therapeutics announces a leadership transition with Mark Velleca, M.D., Ph.D., stepping down as CEO to become a senior advisor effective January 1, 2021. He will remain on the Board of Directors. Jack Bailey, previously a board member and with extensive pharmaceutical experience, will take over as CEO. This transition follows the company's advancements with its lead therapy, trilaciclib, and aims to strengthen its focus on oncology. The board expresses confidence in Bailey's leadership to navigate future challenges and opportunities, highlighting a deep understanding of healthcare market dynamics.
G1 Therapeutics (GTHX) announced two presentations featuring data on the investigational oral CDK4/6 inhibitor, lerociclib, at the ESMO Virtual Congress 2020 from September 19-21. These presentations include updated findings from a Phase 2 trial of lerociclib combined with fulvestrant for HR+, HER2- advanced breast cancer. Key details include:
- Abstract 1407: Updated Phase 2 results.
- Abstract 1417: cfDNA analysis from Phase 1/2 study.
Lerociclib is a differentiated oral CDK4/6 inhibitor, currently in trials for breast cancer and non-small cell lung cancer.
FAQ
What is the current stock price of G1 Therapeutics (GTHX)?
What is the market cap of G1 Therapeutics (GTHX)?
What does G1 Therapeutics, Inc. specialize in?
What is COSELA® (trilaciclib)?
What is the PRESERVE 2 trial?
Where is G1 Therapeutics, Inc. located?
Who are G1 Therapeutics' key partners?
What recent financial achievements has G1 Therapeutics reported?
What is lerociclib?
How can I get more information about G1 Therapeutics?
What types of cancer are G1 Therapeutics’ therapies targeting?
What are G1 Therapeutics’ future goals?
